Related Experiment Video
Updated: Mar 8, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
A hemodialysis cohort study of protocol-based anticoagulation management
S Lamontagne1,2, Tinzar Basein3, Binyue Chang3
1Department of Medicine, University of Massachusetts Medical School, Worcester, USA. slamontagn@bhs1.org.
Insights
A standardized warfarin dosing protocol for hemodialysis patients did not improve anticoagulation control but significantly reduced monitoring resource utilization. This suggests protocol-based management is beneficial for efficiency in chronic hemodialysis care.
Area of Science:
- Nephrology
- Pharmacology
- Clinical Medicine
Background:
- Chronic hemodialysis patients often require warfarin for comorbidities.
- Optimal warfarin monitoring and dose adjustment in this population remain unclear.
- A standardized protocol was implemented to assess its impact.
Purpose of the Study:
- To evaluate the effectiveness of a standardized warfarin dosing protocol.
- To assess changes in anticoagulation efficacy (TTR) and resource utilization (INR measurements).
Main Methods:
- Retrospective analysis of warfarin therapy data from hemodialysis patients.
- Comparison of pre-protocol and on-protocol timeframes.
- Assessment of time within therapeutic INR range (TTR) and weekly INR measurements.
Main Results:
- Time within therapeutic INR range (TTR) showed no significant improvement (51.18% vs. 51.57%).
- Resource utilization decreased significantly, with INR measurements dropping from 1.71 to 1.20 per patient-week.
- p < 0.0001 for reduction in resource utilization.
Conclusions:
- A standardized warfarin dosing protocol did not enhance anticoagulation control in hemodialysis patients.
- The protocol led to a significant reduction in resource utilization.
- Protocol-based warfarin management is supported, with a need for further research on achieving optimal anticoagulation rates.
Background:
Chronic hemodialysis patients frequently require anticoagulation treatment with warfarin for a variety of co-morbidities. The optimal method for monitoring and dose adjustment of warfarin-based anticoagulation in this population, however, remains unclear. To examine this more closely, we reviewed all hemodialysis patients at a single institution on chronic warfarin therapy for a 10-month period prior to and after the institution of a standardized protocol for warfarin dose adjustment and monitoring. Anticoagulation efficacy was assessed by time within the therapeutic INR range (TTR), and resource utilization was assessed by the number of weekly INR measurements required for monitoring.
Results:
We retrospectively analyzed 4481 patient-days of warfarin therapy data (from 25 hemodialysis patients) in the pre-protocol timeframe, and 3308 patient-days of warfarin therapy data (from 21 hemodialysis patients) in the on-protocol timeframe. Time within the therapeutic INR range (TTR) did not improve with institution of the dosing protocol-51.18% using non protocol-based management, and 51.57% using protocol-based management (p 0.73). However, overall resource utilization was reduced with institution of protocolized warfarin monitoring-from 1.71 INR measurements per patient-week pre-protocol, to 1.20 INR measurements per patient-week (p < 0.0001) post-protocol.
Conclusions:
In this single-center study, institution of a standardized dosing protocol in a hemodialysis population on chronic warfarin therapy did not improve the rate of on-target anticoagulation, but did result in significantly lower resource utilization. We support protocol-based warfarin management in the hemodialysis population, but future work should examine the rate of on-target anticoagulation typically achieved in this group.
Related Concept Videos
Hemodialysis III: Nursing Management
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury V: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

